Sugi Predict

Sugi Predict / Targets / CDK3

CDK3

Cyclin-dependent kinase 3 · Q00526 · CDK3 on Sugi Atlas →

14,923 patent compounds predicted against CDK3, 11,430 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1273753 SCHEMBL1273753 1.00 20/20
SCHEMBL1273795 SCHEMBL1273795 1.00 20/20
SCHEMBL1273924 SCHEMBL1273924 1.00 20/20
SCHEMBL1274121 SCHEMBL1274121 1.00 20/20
SCHEMBL1274187 SCHEMBL1274187 1.00 20/20
SCHEMBL1274211 SCHEMBL1274211 1.00 20/20
SCHEMBL1274788 SCHEMBL1274788 1.00 20/20
SCHEMBL1274828 SCHEMBL1274828 1.00 20/20
SCHEMBL1274975 SCHEMBL1274975 1.00 20/20
SCHEMBL1275127 SCHEMBL1275127 1.00 20/20
SCHEMBL1275136 SCHEMBL1275136 1.00 20/20
SCHEMBL1275140 SCHEMBL1275140 1.00 20/20
SCHEMBL1275190 SCHEMBL1275190 1.00 20/20
SCHEMBL1274126 SCHEMBL1274126 0.84 20/20
SCHEMBL1274830 SCHEMBL1274830 0.83 20/20
SCHEMBL1274185 SCHEMBL1274185 1.00 19/20
SCHEMBL1274189 SCHEMBL1274189 1.00 19/20
SCHEMBL1274227 SCHEMBL1274227 1.00 19/20
SCHEMBL1274494 SCHEMBL1274494 1.00 19/20
SCHEMBL1274544 SCHEMBL1274544 1.00 19/20

Clinical trials — most relevant to CDK3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) PHASE3ACTIVE_NOT_RECRUITING
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) PHASE3COMPLETED
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors PHASE1/PHASE2COMPLETED
Palbociclib With Everolimus + Exemestane In BC PHASE1/PHASE2COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy PHASE2COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC PHASE2ACTIVE_NOT_RECRUITING
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer PHASE2COMPLETED
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. PHASE2COMPLETED
Abemaciclib + Pembrolizumab In Glioblastoma PHASE2WITHDRAWN
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) PHASE1COMPLETED
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC PHASE1WITHDRAWN
The SONImage Study nanACTIVE_NOT_RECRUITING
Tka Assay for CDK4/6i nanCOMPLETED
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy nanCOMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDK3 binder may also engage these)

ProteinNameSimilarity
Q5E9Y0 — 0.998 Q5E9Y0 →
P43450 — 0.998 P43450 →
CDK2 Cyclin-dependent kinase 2 0.997 landscape →
P23437 — 0.996 P23437 →
P04551 — 0.996 P04551 →
P23111 — 0.995 P23111 →
P51958 — 0.995 P51958 →
P48963 — 0.995 P48963 →
P24100 — 0.995 P24100 →
Q63699 — 0.994 Q63699 →
P34112 — 0.994 P34112 →
Q9W739 — 0.994 Q9W739 →
Q80YP0 — 0.994 Q80YP0 →
Q27032 — 0.993 Q27032 →
P29619 — 0.993 P29619 →
P51166 — 0.993 P51166 →
Q5RCH1 — 0.993 Q5RCH1 →
Q26671 — 0.992 Q26671 →
O55076 — 0.992 O55076 →
Q9DGD3 — 0.992 Q9DGD3 →
P29618 — 0.992 P29618 →
Q9DG98 — 0.992 Q9DG98 →
Q05006 — 0.992 Q05006 →
Q41639 — 0.991 Q41639 →
Q38773 — 0.991 Q38773 →
P93101 — 0.990 P93101 →
Q2PQN9 — 0.990 Q2PQN9 →
CDK1 Cyclin-dependent kinase 1 0.990 landscape →
Q38772 — 0.990 Q38772 →
P49615 — 0.990 P49615 →